These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22257577)

  • 41. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
    Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
    Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).
    Marin JM; Beeh KM; Clemens A; Castellani W; Schaper L; Saralaya D; Gunstone A; Casamor R; Kostikas K; Aalamian-Mattheis M
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1425-34. PubMed ID: 27418815
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
    LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
    Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bronchodilator effects, pharmacokinetics and safety of PSX1002-GB, a novel glycopyrronium bromide formulation, in COPD patients; a randomised crossover study.
    Singh D; Ravi A; Reid F; Buck H; O'Connor G; Down G
    Pulm Pharmacol Ther; 2016 Apr; 37():9-14. PubMed ID: 26827913
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
    Reisner C; Pearle J; Kerwin EM; Rose ES; Darken P
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1965-1977. PubMed ID: 29950826
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
    Feldman G; Walker RR; Brooks J; Mehta R; Crater G
    Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
    Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
    Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease.
    de la Motte S; Beier J; Schmid K; Pascual S; Jansat JM; Gil EG
    Int J Clin Pharmacol Ther; 2012 Jun; 50(6):403-12. PubMed ID: 22541745
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
    Beeh KM; Korn S; Beier J; Jadayel D; Henley M; D'Andrea P; Banerji D
    Respir Med; 2014 Apr; 108(4):584-92. PubMed ID: 24534204
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ▾Glycopyrronium for COPD.
    Drug Ther Bull; 2013 Jun; 51(6):66-8. PubMed ID: 23744364
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
    Rogliani P; Calzetta L; Ora J; Lipsi R; Segreti A; Matera MG; Cazzola M
    Eur J Pharmacol; 2015 Aug; 761():383-90. PubMed ID: 25952728
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New therapeutic choice for COPD: glycopyrronium bromide, a long-acting muscarinic antagonist].
    Yoshisue H; Kozawa M; Hiratsuka M; Nakanishi M
    Nihon Yakurigaku Zasshi; 2013 Oct; 142(4):190-9. PubMed ID: 24107524
    [No Abstract]   [Full Text] [Related]  

  • 55. Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.
    Demin I; Bartels C; Graham G; Bieth B; Gautier A; Tillmann HC; Sechaud R
    Int J Clin Pharmacol Ther; 2016 Jun; 54(6):405-15. PubMed ID: 27049057
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants.
    Ortiz S; Flach S; Caracta C; Gil EG; Jansat JM
    J Clin Pharmacol; 2012 Jun; 52(6):819-27. PubMed ID: 21628603
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparing the cardiovascular therapeutic indices of glycopyrronium and tiotropium in an integrated rat pharmacokinetic, pharmacodynamic and safety model.
    Trifilieff A; Ethell BT; Sykes DA; Watson KJ; Collingwood S; Charlton SJ; Kent TC
    Toxicol Appl Pharmacol; 2015 Aug; 287(1):9-16. PubMed ID: 26026369
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
    Martinez FJ; Rabe KF; Ferguson GT; Fabbri LM; Rennard S; Feldman GJ; Sethi S; Spangenthal S; Gottschlich GM; Rodriguez-Roisin R; Arora S; Siler TM; Siddiqui S; Darken P; Fischer T; Maes A; Golden M; Orevillo C; Reisner C
    Chest; 2017 Feb; 151(2):340-357. PubMed ID: 27916620
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use.
    Chiu MH; Al-Majed NS; Stubbins R; Pollmann D; Sandhu RK
    BMC Res Notes; 2016 Jun; 9():310. PubMed ID: 27301406
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study.
    Hashimoto S; Ikeuchi H; Murata S; Kitawaki T; Ikeda K; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2543-2551. PubMed ID: 27785010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.